- Home
- OMF vs GH Comparison
OMF vs GH Comparison
Compare OMF & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMF
- GH
- Stock Information
- Founded
- OMF 1920
- GH 2011
- Country
- OMF United States
- GH United States
- Employees
- OMF N/A
- GH N/A
- Industry
- OMF Finance: Consumer Services
- GH Medical Specialities
- Sector
- OMF Finance
- GH Health Care
- Exchange
- OMF Nasdaq
- GH Nasdaq
- Market Cap
- OMF 6.2B
- GH 4.9B
- IPO Year
- OMF 2013
- GH 2018
- Fundamental
- Price
- OMF $51.82
- GH $40.62
- Analyst Decision
- OMF Buy
- GH Strong Buy
- Analyst Count
- OMF 11
- GH 21
- Target Price
- OMF $57.40
- GH $52.81
- AVG Volume (30 Days)
- OMF 977.5K
- GH 2.3M
- Earning Date
- OMF 04-29-2025
- GH 04-30-2025
- Dividend Yield
- OMF 8.03%
- GH N/A
- EPS Growth
- OMF N/A
- GH N/A
- EPS
- OMF 4.73
- GH N/A
- Revenue
- OMF $2,583,000,000.00
- GH $773,996,000.00
- Revenue This Year
- OMF $74.73
- GH $23.05
- Revenue Next Year
- OMF $7.68
- GH $21.40
- P/E Ratio
- OMF $10.96
- GH N/A
- Revenue Growth
- OMF 0.94
- GH 28.20
- 52 Week Low
- OMF $38.00
- GH $20.14
- 52 Week High
- OMF $58.90
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- OMF 56.83
- GH 48.45
- Support Level
- OMF $48.79
- GH $37.73
- Resistance Level
- OMF $52.71
- GH $39.63
- Average True Range (ATR)
- OMF 1.14
- GH 1.60
- MACD
- OMF 0.03
- GH -0.01
- Stochastic Oscillator
- OMF 75.37
- GH 60.00
About OMF OneMain Holdings Inc.
OneMain Holdings Inc is a consumer finance company providing loan products to customers through its branch network and the internet. The company provides personal loan products; offers credit cards; offers optional credit insurance and others; offers a customer-focused financial wellness program, and acquisitions and dispositions of assets and businesses. It provides origination, underwriting, and servicing of personal loans to non-prime customers. The company's reportable segment is Consumer and Insurance. The main source of revenue is net interest income.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.